| **Table D-2. Evidence table for studies assessing hormonal stimulation testing** | | | |
| --- | --- | --- | --- |
| **Study Description** | **Population Description** | **Pre-testing Levels** | **Post-testing Levels** |
| Author:  Davenport et al., 1995  Country:  UK  Setting:  Hospital  Enrollment period:  1974 to 1990  **Design:**  Prospective cohort | Groups:  G1: Particpants diagnosed as anorchic following surgical exploration  G2: Participants diagnosed with bilateral, intraabdominal testes of normal volume following surgical exploration  G3: Participants diagnosed with either unilateral, intraabdominal testes only or with bilateral dysplastic testes following surgical exploration  Participants received three doses of IM hCG on successive days. Dosage varied by age:  <1 yr : 500 units/dose  1-10 yrs: 1000 units/dose  >10 yrs: 1500 units/dose  Inclusion criteria:  See exclusion criteria  Exclusion criteria:   * Children with ambiguous genitalia or intersex * History suggestive of neonatal torsion or trauma   N at enrollment (N testes):  G1: 8 (0)  G2: 14 (28)  G3: 9 (NR)  N at follow-up (N testes):  G1: 8 (0)  G2: 14 (28)  G3: 9 (NR)  Age, median yrs (range):  9 (1-12)  Comorbidities, n (%):  NR | Hormone levels:  Testosterone, basal median value (range):  **G1:** 0.64 (0.5-2)  **G2:** 0.5 (0.3-4.6)  **G3**: 0.7 (0.4-4) | Hormone levels:  Testosterone, peak median value (range):  **G1:** 0.7 (0.3-2)  **G2:** 5.1 (1.8-38.9)  **G3**: 1.8 (0.7-21.7)  Overall proportion with surgery:  31 (100)  Proportion with hormone response followed by surgery:  31 (100)  Proportion with no hormone response followed by surgery:  NR  Proportion of testes palpable after testing:  NR  Confirmation of presence of testes:  NA |

| **Table D-2. Evidence table for studies assessing hormonal stimulation testing (continued)** | | | |
| --- | --- | --- | --- |
| **Study Description** | **Population Description** | **Pre-testing Levels** | **Post-testing Levels** |
| Author:  Merksz et al., 1992  Country:  Hungary  Setting:  Hospital  Enrollment period:  NR  **Design:**  Prospective cohort | Groups:  G1: Particpants with bilateral undescended testes  G2: Participants with undescended testes with hypospadia  Participants received 4500 IU of hCG over three consecutive days  Inclusion criteria:   * Suspected impaired androgen secretion * Impalpable testes * Hypospadias associated with undescended testes   Exclusion criteria:   * Unilateral retention * Both testes palpable inguinally before surgery or found to be normally developed during surgery   N at enrollment (N testes):  G1: 20 (40)  G2: 10 (17)  N at follow-up (N testes):  G1: 20 (40)  G2: 10 (17)  Age, range yrs:  1-12  Comorbidities, n (%):  Hypospadias: 10 (33.3) | Hormone levels:  Serum testosterone value, basal median value (range):  **G1:** 0.67 (0.01-2)  **G2:** 0.53 (0.01-1.4) | Hormone levels:  Serum testosterone value, median value (range):  **G1:** 4.16 (0.5-14.5)  **G2:** 4.18 (0.42-13.5)  Overall proportion with surgery:  NR  Proportion with hormone response followed by surgery:  NR  Proportion with no hormone response followed by surgery:  NR  Proportion of testes palpable after testing:  NR  Confirmation of presence of testes:  NR |